To study the tumor specificity and antitumor activity of the replication-competent oncolytic adenovirus TOA02, which is controlled by a modified human telomerase reverse transcriptase (hTERT) promoter and expresses granulocyte macrophage colony-stimulating factor (GM-CSF). The wild-type hTERT promoter was modified, by inserting two E2F-binding sites. The effect of the modified hTERT on the viral yield and cytotoxicity of TOA02 were determined in vitro with a panel of tumor cells and normal cells, to evaluate tumor specificity; the effect on the antitumor efficacy and toxicity of TOA02 were determined in vivo, to evaluate the therapeutic potential of the adenovirus. The TOA02 adenovirus, which contained the modified hTERT promoter, produced a higher yield of virus in telomerase-positive and retinoblastoma-defective human cells, and a lower yield of virus in normal human cells than the wild-type adenovirus. A single injection of TOA02 showed strong antitumor efficacy in nude mice with human head/neck and hepatocellular carcinoma xenografts, and the efficacy further improved when used in combination with chemotherapy and with different routes of administration and regimens. In immunocompetent mice, the addition of GM-CSF produced a stronger antitumor activity and induced more mature dendritic cells and macrophages. The TOA02 adenovirus showed strong tumor-cell selectivity in vitro and antitumor efficacy in mouse models of human head/neck and hepatocellular cancer, suggesting that TOA02 has potential clinical applications for the treatment of solid tumors.
Introduction
One strategy for tumor therapy involves infection with a replication-competent adenovirus that lyses the infected cells. Viral replication is restricted to tumor cells by placing one or two essential viral genes under the control of tissue-specific transcription-regulatory elements 1 such as the a-fetoprotein promoter, 2 the prostate-specific promoter and enhancer, 3 the bladder endothelium-specific promoter 4 and the colon cancer-specific promoter. 5 Human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase, is involved at a critical point in the cell cycle and is aberrantly expressed in approximately 85% of tumor cells. 6 Several research groups have developed hTERT-specific oncolytic adenoviruses for cancer gene therapy. 7, 8 However, some studies have detected hTERT-specific viral gene expression in normal cells. 9, 10 Bilsland et al. 11 reported the detection of viral replication, E1a expression, and cytotoxicity of wildtype hTERT promoter-controlled replicating adenovirus in normal cells, suggesting the need for an improved hTERT promoter for tumor-specific oncolytic adenoviruses. Several research groups have attempted to improve the selectivity of telomerase-specific oncolytic adenovirus to tumor cells by introducing other transcriptional-factor-binding sequences such as c-Myc and Sp1-binding sites, or E-boxes, into the core sequence of the hTERT promoter. 12, 13 Viral replication and cytotoxicity was reduced in normal cells, but was also reduced in all malignant cells.
Similar to hTERT, the E2F-1 promoter is also used by oncolytic adenoviruses and exhibits a highly selective replication in retinoblastoma (Rb) pathway-defective cells 14 (that is, most tumor cells). However, there was limited specificity for the multitude of genetic and phenotypic changes occurring in primary tumor cells. The E2F-binding sites in the E2F-1 promoter are the key sequences involved in the interaction with the E2F-pRB complex, 15 and these sequences are sufficiently short to be inserted into the hTERT promoter without deleting most of its own regulatory elements; it was thus hypothesized that the wild-type hTERT promoter used in oncolytic adenoviruses can be modified with two E2F-1-binding sites to significantly enhance its activity in tumor cells, but not in normal cells. As the majority of tumor cells are both hTERT positive and Rb defective, the modified hTERT promoter may result in the dual dependency of an oncolytic adenovirus for telomerase expression and deficiency of the Rb pathway.
To generate antitumor activity in uninfected local tumors and distant metastasized tumors, the cDNA of human granulocyte macrophage colony-stimulating factor (GM-CSF) was inserted into the E3 region of the TOA02 adenoviral genome. GM-CSF has previously been demonstrated to be a potent inducer of specific, longlasting antitumor immunity in both animal models and human clinical trials. 16 As GM-CSF was placed under the control of the endogenous viral E3 promoter, which is transactivated by E1a, the modified telomerase promoter might eventually control GM-CSF expression. Following infection by TOA02, tumor cells are lysed and tumor antigens are exposed to the patient's immune system, thereby inducing a tumor-specific immune response.
In this study, the tumor selectivity, cytotoxicity and GM-CSF production of TOA02 were evaluated in several different cancer cell lines. The antitumor efficacy of TOA02 as monotherapy or in combination with doxorubicin was studied. The antitumor efficacy KH920, a murine homolog of TOA02, was also tested in an immunocompetent mouse tumor model.
Materials and methods
Cell and culture methods Several types of cell lines were used in the cytotoxicity assays, virus burst size assays and human GM-CSF production assays. Cells that have previously been demonstrated to have both a defective Rb pathway and hTERT expression were cultured as per the recommendation of the American Type Culture Collection (Manassas, VA). 14 19 were also used to evaluate the Rb dependence on the modified promoter. GM-CSF-dependent TF-1 acute myeloblastic leukemia AML cells were used for the bioactivity assay of GM-CSF. All these cells were cultured in the medium RPMI-1640 (JRH Biosciences Inc., Lenexa, KS) containing 10% fetal bovine serum (FBS; Hyclone, Irvine, CA), 2.05 mmol l À1 glutamine, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin.
Promoter cloning and tumor specificity
The hTERT promoter fragment corresponding to nucleotides À167 to þ 82 relative to the transcription initiation site was amplified from human genomic DNA by PCR and flanked with BamH I sites at the 5 0 -and 3 0 -ends to facilitate further cloning. To add E2F-binding sites, nucleotides from À18 to À3 and from þ 5 to þ 20 relative to the transcription initiation site were changed into 5 0 -TTCCGCGGCAACGCCC-3 0 and 5 0 -TTCGCG GCGCGAGTTT-3 0 by site-directed mutagenesis as described previously. 3 The modified tumor-specific promoter was inserted into a plasmid to regulate expression of the luciferase reporter gene (hTERT-Luc and modified hTERT-Luc (mhTERT-Luc)) for promoter activity assays following methods described previously. 20 
Viruses
The recombinant adenoviruses were generated following a previously described procedure. 3 All cloning steps to modify the E1 region of the adenoviral genome were done using plasmid pXC.1 (Microbix Biosystems Inc., Toronto, Ontario, Canada), which contains Ad5 bp 22-5790, including the inverted terminal repeat, the packaging sequence and the Z1a and Z1b genes inserted into pBR322. The mhTERT promoter was inserted into the adenoviral genome using conventional molecular cloning techniques to control Z1a expression, resulting in a plasmid called TOA02-a. To create TOA02-b, the gp19k gene in the E3 region was replaced with the cDNA of GM-CSF. The procedure to generate this plasmid has been described previously.
2 Plasmid DNA of TOA02-a and TOA02-b was co-transformed into HeLa cells, resulting in a virus called TOA02. The virus was purified using two rounds of cesium chloride density gradient centrifugation. Virus particle titers were determined through a spectrophotometric method described previously. 21 To confirm the genome structure, viral DNA were extracted from TOA02 using QIAamp DNA Blood Mini Kits (Qiagen, Hilden, Germany). Then the DNA solution (20 ml, 1 mg) was digested with 10 U of HindIII restriction endonucleases according to the manufacturer's instructions (Takara, Dalian, China). DNA fragments were separated by electrophoresis in 1.3% agarose gels (Sigma, St Louis, CA). Bands were stained with ethidium bromide (0.1 mg ml
À1
) and visualized by using a Gel Doc XR TM image analysis system (Bio-Rad, Hercules,CA).
Cytotoxicity assays
The cytotoxicity of oncolytic adenoviruses on a panel of tumor and normal cells was determined by exposing cells to serial dilutions of virus for 10 days, after which an 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTT) cytotoxicity assay (CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay, Promega, Madison, WI) was performed according to the manufacturer's protocol.
Virus production assays
To examine the viral replication abilities, actively dividing tumor cells were seeded into six-well tissue culture dishes at 5 Â 10 5 cells per well. After 1 day, the seeded cells were infected with viruses at 50 particles per cell. After 3 h of incubation, the infection medium was removed and the cells were rinsed twice with serum-free medium, then 3 ml of RPMI-1640 medium containing 10% FBS was added and incubated at 37 1C. After 72 h, both medium and cells were subjected to three cycles of freeze-thaw, and centrifuged to collect the supernatant. The plaque assay was conducted to determine the burst size following the previously described protocol of Li et al.
2
Quantitative reverse transcriptase-PCR To measure the E1a expression, human foreskin keratinocytes hFKs (hTERT n and Rb w ) and hFKs-E7 cells (hTERT p and Rb d ) were infected with TOA02 or wildtype Ad5 at 1000 viral particles per cell. Twenty-four hours after infection, cells were rinsed and trpysinized to remove the virus, and quantitative reverse transcriptase-PCR was performed on RNA isolated using RNAzol B (Tel-TEST, Friendswood, TX). 22 The expression level (transcription) of E1a for each virus was normalized to viral DNA copy number (hexon DNA copy number).
GM-CSF production
To evaluate human GM-CSF expression by TOA02, tumor cells were infected at the multiplicities of infection (MOIs) of 1 and 10. Supernatants were collected after 24 and 72 h and subjected to enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN) to quantify the total amount of GM-CSF expression. Cultured cell supernatants were diluted 10-to 1000-fold in assay buffer. Data were read on a spectrophotometer at 450 nm and analyzed using the SoftMax software package. The standard curve for human GM-CSF typically had an R 2 -value 40.995 and the sensitivity of the assay was typically no less than 7.8 pg ml À1 . Biological activity of GM-CSF was measured in TF-1 cells as described previously. 23 In vivo antitumor efficacy studies Antitumor efficacy studies were performed using tumor xenografts. Xenograft models were established in 6-to 8-week-old female nude mice subcutaneously injecting 2 Â 10 6 of SCC9 or Hep3B cells in Matrigel (injection volume of 0.2 ml). When the tumors reached 100-200 mm 3 , the mice were randomly distributed into several treatment groups. For the SCC9 model, each animal was intratumorally injected five times with TOA02 at a concentration of 3 Â 10 10 viral particles or with vehicle (phosphate-buffered saline (PBS) with 10% glycerol) per dose. For the Hep3B model, each animal was intratumorally or tail vein injected three times with TOA02 at a concentration of 5 Â 10 10 viral particles or with vehicle. The antitumor synergy of TOA02 in combination with doxorubicin was evaluated in Hep3B subcuteneously xenograft tumor model. Three groups of animals were treated with TOA02 at 1 Â 10 10 viral particles doxorubicin (10 mg kg À1 ) or both TOA02 and doxorubicin using the same regimen as for monotherapy. Tumor volume was measured twice weekly in two dimensions for the duration of the study beginning on day 1, and the volume was calculated as width 2 Â length/2. Body weight was measured once per week for the duration of the study. Mice were euthanized if the tumor volume exceeded 2000 mm 3 or if they lost 410% of their initial body weight. The immunocompetent mouse tumor model was also used to evaluate the tumor-specific immunity induced by GM-CSF. Briefly, 6-to 8-week-old female C57BL/6 mice received a subcutaneous injection of 1 Â 10 7 of CMT-64 cells in Matrigel (injection volume of 0.2 ml) and were then randomized into treatment groups when the tumors reached 80-200 mm 3 . Each animal received three intratumoral injections (on alternate days) with 3 Â 10 10 viral particles per dose of TOA02 or KH-920, which encodes murine GM-CSF, but is otherwise the same as TOA02. Control mice received vehicle (PBS with 10% glycerol) alone. To evaluate the immune function stimulated by the murine GM-CSF, animals with subcutaneous CMT-64 tumors were intratumorally injected daily with KH920 for three times at 3 Â 10 10 viral particles per dose. Three days after the last dose, the mice were killed and the tumordraining lymph nodes were collected and cut into small pieces, after which the tissue was mechanically disaggregated through a stainless steel sieve and centrifuged at 15 000 r.p.m. for 15 min at 4 1C. After that, the lymphocyte suspension was washed twice with PBS and was stained with biotin-conjugated hamster antimouse CD11c MAb (HL3, BD, Bioscience, Palo Alto, CA). The suspension was then subjected to the FACSCalibur flow cytometry (Becton Dickinson, Mountain View, CA), using forwardand side-scatter characteristics to exclude dead cells.
Results

Virus structure
The genomic structure of the oncolytic adenoviral vector TOA02 is shown schematically in Figure 1a . TOA02 differs from wild-type Ad5 in two regions of the genome. First, the modified promoter (mTelo) of the human telomerase reverse transcriptase gene, which was genetically engineered to include two E2F-1-binding sites, was cloned in the place of the endogenous E1a promoter in the Ad5 backbone to selectively regulate E1a expression and restrict viral replication to tumor cells. Second, the coding region of the gp19-kDa glycoprotein gene (gp19k) of the E3 region was replaced with the cDNA of the GM-CSF gene. Expression of GM-CSF was therefore under the control of the E3 promoter. As E1 gene products activate the E3 promoter, both viral replication and GM-CSF expression must ultimately be under the control of the tumor-selective mhTERT promoter. The rest of the viral genome backbone, including the packaging signal, E2, E4, late protein regions and inverted terminal repeats, were identical to the wild-type Ad5 genome. The structure of the viral genome was confirmed by restriction enzyme analyses of the purified viral DNA and sequence determination of the modified regions of the genome (Figure 1b ). An alternate oncolytic adenovirus KH920 was constructed that was identical to TOA02 except that it carried the cDNA for murine GM-CSF rather than human GM-CSF.
Tumor-specificity of the mhTERT promoter mTelo The promoter from the hTERT gene was cloned by PCR and confirmed by sequencing. To increase the tumor selectivity of the hTERT promoter, two E2F-1-binding sites (5 0 -TTTCCGCGGCAA-3 0 and 5 0 -TTCGCGGCGC GAGTTT-3 0 ) were introduced into the promoter by mutagenesis (Figure 1c ). Tumor specificity of the modified promoter was validated using the luciferase reporter gene in a cell-based transient transfection system as described previously. 20 To calibrate the transfection efficiency of different cell lines, the b-galactosidase activity was used to normalize the luciferase activity, which is summarized in Figure 2a . The results indicated that both the modified (mTelo) and wild-type promoter (Telo) are highly active in telomerase-positive and Rbdefective cells (LoVo, Hep3B, LNCaP and A549), but the modified promoter (mTelo) resulted in significantly higher reporter gene activity, especially in the LNCaP cell line (by more than 18-fold). In hTERT-negative and Rb wildtype cell lines (MRC-5, BJ and hMVEC), however, the wild-type promoter was found to have low levels of reporter gene activity, whereas activity of the modified promoter was almost suppressed. The activity ratio of the promoters in the same pair of cell lines was significantly increased (5 in Hep3B/MRC-5 for the wild-type promoter and 180 for the modified promoter), suggesting that the modified telomerase promoter with two E2F-binding sites has a much improved tumor cell selectivity (Figure 2) .
To examine the Rb status dependence of the modified telomerase promoter in the adenoviral setting and the selectivity of the resulting adenovirus, expression levels of E1a and GM-CSF were measured in the TOA02-infected 
GM-CSF armed
hFKs and hFKs-E7 cells, a matched isogenic pair of hTERT-negative cell lines that have a different Rbpathway status. hFKs-E7 is a human papillomavirus (HPV) E7-transformed cell derived from hFKs, in which the HPV E7 has disrupted the pRB-E2F complex, 24 resulting in high levels of free-E2F transcription factor. The deregulation of the Rb pathway has been noted previously in E7-infected cell lines. 25 The E1a mRNA level 24 h after infection was assessed by quantitative PCR. Following infection with 1000 viral particles per cell, an average of 2.2 Â 10 2 copies of E1A mRNA was observed in hFKs cells, compared with 2.4 Â 10 4 copies in hFKs-E7 cells (Figure 2b) . A separate experiment in this cell-line pair demonstrated the dependence of GM-CSF production on a defective Rb pathway; 3700-fold more GM-CSF was measured in TOA02-infected hFKs-E7 cells than in hFKs cells (Figure 2b) . These results showed that, even in hTERT-negative cells, the E2F-binding sites inserted into the hTERT promoter can selectively drive the high-level expression of adenoviral E1a gene and the downstream E3 promoter-controlled human GM-CSF in Rb pathway-defective cells.
Following adenovirus infection of the target cells, the amount of viral progeny reflects the replication efficiency. The production of TOA02 in human cancer cell lines (Rb defective and hTERT positive) and human normal cells (Rb normal and hTERT negative) was compared with that of wild-type adenovirus Ad5 (Figure 3a) . TOA02 replicated in the Rb-defective human cancer cells Lovo (colorectal cancer), LNCaP (prostate cancer), SCC4 (head and neck cancer), Hep3B (hepatocellular carcinoma) and A549 (lung cancer), as efficiently as wild-type adenovirus Ad5, producing similar levels of viral progeny (4000-7000 plaque-forming units per cell), but was highly attenuated (B100-fold) in Rb-normal and hTERT-negative human cells, including BJ (foreskin fibroblasts) and retinal pigment epithelium RPE. Ad5 produced similar levels of viral progeny in both tumor and primary cells, whereas TOA02 produced 42 log more viral progeny in human tumor cell lines than in primary cells.
Cytotoxicity in vitro
Cytotoxicity of TOA02 in tumor and primary cells was examined in the MTT cell viability assay to determine the tumor selectivity and effectiveness in lysing tumor cells. Data presented in Figure 3b indicate that TOA02 was cytotoxic to the human tumor cells (SCC9, LoVo, Hep3B, A549) but highly attenuated in normal human cells (MRC-5 and BJ). By day 10 following infection with 1 MOI of TOA02, for example, the viability of human tumor cell lines was reduced by 10-20% compared with 495% viability for normal cells. This result suggests that TOA02 preferentially kills tumor cells, but is highly attenuated in normal cells.
GM-CSF expression
The amount of human GM-CSF expression was measured in human tumor cell lines and primary cells following infection with TOA02 at 1 or 10 viral particles per cell. Supernatants were collected after 24 h, and the total amount of GM-CSF protein expressed was quantitated using enzyme-linked immunosorbent assay. A doseresponse for GM-CSF expression was seen in all of the cell types tested (Table 1) , and the expression level varied o15-fold among the TOA02-infected human tumor cell lines at each MOI. However, significant differences in the levels of GM-CSF expression were seen between the tumor cell lines and the normal foreskin fibroblast cell BJ. For example, at an MOI of 10, the amount of GM-CSF protein expressed in human tumor cell lines was 40-to 300-fold higher than that expressed in BJ. GM-CSF bioactivity assay with TF-1 cells showed that the GM-CSF expressed in the human tumor cells was biologically active (Table 1) . 
GM-CSF armed Adv with modified hTERT promoter N Lei et al
Antitumor efficacy in immunodefective human tumor xenografts The antitumor efficacy of TOA02 as a monotherapy was evaluated in two subcutaneous human tumor xenografts. A head and neck tumor SCC9 xenograft was established in nude mice, which were then intratumorally injected with TOA02 (Figure 4a ). Significant antitumor efficacy was observed following five injections of TOA02 at a concentration of 3 Â 10 10 virus particles per dose (Po0.05) compared with vehicle-injected tumors. By day 30, vehicle-treated tumors exhibited an average growth rate of 50 mm 3 day À1 and had increased in volume by 16-fold on day 1 (baseline). However, the mean tumor size of TOA02-treated groups increased slowly at an average rate of 16.7 mm 3 day
À1
, reaching a maximum size (4-fold that of the baseline) by day 18 and then decreasing at a rate of 3 mm 3 day À1 to about 3-fold that of the baseline by day 50, where they stabilized.
In the subcutaneous hepatocellular cancer Hep3B tumor model, significant inhibition in tumor growth was observed following three intratumoral or tail vein injections of 5 Â 10 10 viral particles per injection of TOA02 (Figure 4b) . By day 42, the average volume of vehicle-treated tumors grew by nearly 9-fold compared with the baseline; however, there was a o1.5-fold growth in the TOA02 tail vein administration group (Po0.05), although the TOA02 intratumoral administration group had almost complete tumor regression at the same time point. Body weight and weight gain were generally unaffected in all the treatment groups (data not shown).
The antitumor efficacy of TOA02 in combination with chemotherapy was assessed in Hep3B tumor xenografts. Animals were treated with TOA02 alone, doxorubicin alone or both agents, as indicated in Figure 4c . A significant decrease in tumor volume between the control group and the treatment groups (Po0.05) was evident. By day 42, for example, the average tumor volume of the vehicle control group grew to nearly 10-fold that of the baseline, whereas the average tumor volume was 6-fold for doxorubicin alone and 3.5-fold for TOA02 alone. Importantly, significant differences in efficacy were observed between the combination and monotherapy treatment groups (Po0.05), with the highest antitumor efficacy obtained in the combination treatment group compared with the monotherapy group. Antitumor efficacy in an immunocompetent tumor model Female C57BL/6 mice bearing a subcutaneous murine lung carcinoma CMT-64 were used as an immunocompetent tumor model to compare the effect of TOA02 as reported previously. 26 As human GM-CSF is not active in mice, the analog of TOA02, KH920, which is identical to TOA02 but encodes the murine GM-SCF, was included in this study. Following a regimen of intratumoral injections administered three times every other day at a concentration of 3 Â 10 10 viral particles per dose, both TOA02 and KH920 demonstrated remarkable antitumor efficacy ( Figure 5a) ; however, KH920 was significantly more effective in this model than TOA02 (Po0.05). By day 42, the tumor volume of the vehicle-treated group increased by 14-fold that of the baseline. The TOA02 group only increased by approximately 4-fold. Furthermore, the KH920-treated tumor grew slowly to a maximum size (B2.1-fold) by day 21, and decreased to baseline by day 42 (Po0.05).
Using the same model, the antitumor immunity induced by GM-CSF was examined. Tumor-bearing animals were injected intratumorally daily with KH920 or TOA02 for three times at a dose of 3 Â 10 10 viral particles per dose. Three days after the last dose, the tumor-draining lymphocytes were harvested and stained with CD11c, a surface marker for dendritic cells and macrophages, 27 after which the production of CD11c þ cells were analyzed with fluorescence-activated cell sorting. Data presented in Figure 5b show that the percentage of CD11c þ cells in the TOA02-treated group was as low as that in the vehicle-treated group (1.10±0.41 vs 0.85±0.22%; P40.05), demonstrating the species-specificity of GM-CSF. In contrast, over 5.6-fold more CD11c þ cells were detected in the lymph nodes of KH920-treated mice compared with TOA02-treated mice (6.12±0.86 vs 1.10±0.41%; Po0.05). These data provide evidence that, armed with GM-CSF, TOA02 exhibits an improved antitumor immune response by stimulating the proliferation and maturation of host 
Discussion
Telomerase is essential in about 85% of human cancers, but it is not expressed in most normal tissues. 28 The wildtype hTERT promoter has therefore been used as the transcriptional regulatory element to generate conditionally replicating oncolytic adenoviruses with high tumor specificity in most previous studies. 29 However, the relatively weak antitumor activity obtained in some tumor cells and the nonspecific viral replication obtained in normal cells have restricted the potential utility of such agents. For instance, recent work published by Bilsland et al. 11 indicated that high levels of viral DNA and E1a expression are detectable in both cancerous and normal cells following infection of the adenovirus controlled by the wild-type hTERT promoter. Therefore, there is a practical requirement to enhance the specificity of this promoter to improve its usefulness in cancer gene therapy. In this study, TOA02, a conditionally replicating adenovirus based on serotype 5, which bears two genomic modifications distinguishing this agent from the other adenoviruses, was constructed. A multiple-regulation strategy has been used to improve the antitumor efficiency of conditionally replicating adenoviruses. 30, 31 For example, an oncolytic adenovirus, CG5757, 17 in which the E2F-1 promoter and wild-type hTERT promoter control both the E1a and E1b genes, respectively, was described. Although this virus exhibited enhanced selective replication and cytotoxicity in hTERT-positive and Rb-defective tumor cells, the basal and/or periodic expression of telomerase in some tumor cells 32, 33 still needs to be addressed.
To increase the tumor specificity of the hTERT promoter, the wild-type sequence of the promoter was modified to include two E2F-1-binding sites; following this the modified promoter (mTelo) possessed improved tumor specificity in the report gene system and, more importantly, the mTelo promoter maintained the higher tumor selectivity, even in the oncolytic virus setting. Previously, expression and activity in both normal and tumor cells through the E2F-1-binding sites in the hTERT promoter has been reported, 34 suggesting that it is reasonable to establish a dual-dependency promoter by inserting the E2F-1-binding sites into the core sequence of the wild-type hTERT promoter. Theoretically, the high levels of free-E2F-1 transcriptional factor in Rb-defective hTERT-positive tumor cells can bind to E2F-1-binding sites, synergistically activate and elevate the transcriptional activity of the hTERT promoter. On the other hand, even though there is telomerase activity in Rb-normal cells, the low level of transcriptional activity of the hTERT promoter can be further attenuated in the presence of the pRb-E2F-1 complex, restricting the outtarget viral replication and cytotoxicity.
Consistently, these data have demonstrated that in hTERT-positive and Rb-defective cells, both modified and wild-type hTERT promoters drove a high level of luciferase expression, but the modified hTERT promoter resulted in significantly higher expression than the wild type. In contrast, the modified promoter was silent, whereas the wild-type promoter produced low levels of expression in hTERT-negative and Rb-normal cells. These results strongly indicate that the activity of the mhTERT promoter in TOA02 was enhanced in tumor cells, both hTERT positive and Rb defective. Furthermore, the dependence of TOA02 on the Rb status was examined by measuring expression levels of E1a and GM-CSF in hTERT-negative hFKs (Rb-normal) and hFKs-E7 (Rb-defective) cell lines. The hFKs-E7 cell line is formed by transforming hFKs with the E7 gene of HPV16, resulting in the disruption of the Rb pathway. Following infection with TOA02, 100 times more E1a mRNA and 37 000 times more GM-CSF mRNA were detected in hFKs-E7 compared with hFKs. In the same study, wild-type adenovirus led to similar levels of E1a mRNA in both cell lines (4422 vs 4765). Therefore, the expression of the E1a and GM-CSF in the E3 region are highly dependent on the Rb status of cells.
The improved tumor cell selectivity was further confirmed in viral replication and cytotoxicity studies. Nearly 100 times more viral progeny were found in the Rb-defective and hTERT-positive tumor cells after infection, compared with the Rb-normal and hTERTnegative normal human cells. Although TOA02 is highly cytotoxic to hTERT-positive and Rb-defective tumor cells, it is less cytotoxic to normal cells. These data suggest that the modified hTERT promoter possesses superior tumor specificity over the wild-type promoter and is dependent on the upregulation of telomerase expression and deficiency in the Rb pathway.
Another important feature of TOA02 is the inclusion of the cDNA of human GM-CSF in the E3 region. It is not feasible at the present time to deliver adenovirus to achieve therapeutic effects in humans through a systemic delivery system, and most patients with cancer die from distant tumors or metastases. 3, 35 Thus, it is important to establish a systemic effect from a localized treatment. Therapeutic cancer vaccines have recently emerged as a viable approach for obtaining a systemic antitumor effect. 36, 37 Recently, preliminary results from a clinical trial for a GM-CSFexpressing oncolytic adenovirus (CG0070) for patients with recurrent bladder cancer demonstrated three complete responses in nine patients treated with a single intravesicle injection, suggesting an important role for GM-CSFinduced tumor-specific immune responses (Donald L Lamm, American Urological Association, 2006 annual meeting, May 22, Atlanta; and personal communication). In TOA02, the cDNA of GM-CSF is inserted in place of the gp19k gene, and its expression is under the control of the endogenous E3 promoter. As the E3 promoter is activated by the E1a products, the expression of GM-CSF is ultimately controlled by the modified hTERT promoter. Studies have revealed that the production of biologically active GM-CSF found in tumor cell lines at an MOI of 10 was approximately 3-to 20-fold higher than the levels (40 ng per ml per 10 6 cells per 24 h) reported as sufficient to induce an immune response for tumor vaccination in in vivo models. 16 In the immunocompetent C57BL/6 mouse tumor model, where the mice bear subcutaneous CMT-64 tumors, it was found that a mouse GM-CSF-expressing adenovirus, KH920, the homolog of TOA02 that carried the cDNA of murine GM-CSF, resulted in a stronger antitumor efficacy than TOA02. Fluorescence-activated cell sorting analysis further showed a significantly higher proportion of CD11c þ cells, including dendritic cells and macrophages, in tumor-draining lymph nodes from KH920-treated mice than TOA02-treated animals, suggesting a GM-CSFinduced immune response. Therefore, the potential systemic antitumor immune response resulting from local delivery of TOA02 could be achieved by oncolytic lysis of tumor cells adjacent to the injection site and a nonspecific inflammatory reaction could be achieved through the infiltration of neutrophils and eosinophils at an early stage. Tumor antigen released from the lysed cells could then be picked up by mature immune cells recruited by GM-CSF, such as T cells, B cells, natural killer cells, granulocytes, macrophages and dendritic cells, which may result in a local and systemic antitumor immunity. Owing to the species specificity of the TERT promoter, 38 it is anticipated that the higher transcriptional activity of the hTERT promoter in TOA02 will drive higher levels of GM-CSF expression in immunocompetent humans than in mice, leading to a more activated antitumor immune response. However, the reason for the similar proportions of CD11c þ in the TOA02 treatment group and vehicle group (0.93 vs 0.81) is not entirely clear. One potential explanation is that intratumoral injection of Ad5 vector can effectively evade the preexisting Ad immunity. 39 In a preclinical study of CG0070, 14 a similar phenomenon was observed by histochemical examination of the virus-injected tumors, which showed that both human and murine GM-CSF-expressing adenovirus resulted in necrosis and mononuclear cell infiltration into the tumor, but that only murine GM-CSF could induce eosinophil infiltration and activate the consequent immune response. The actual immune mechanisms involved in this mechanism need to be further studied.
Strong antitumor activity was documented in the head and neck cancer SCC9 and liver cancer Hep3B xenograft models. Synergistic antitumor efficacy was also observed when TOA02 was combined with doxorubicin. Similar viral yield levels of TOA02 and wild-type adenovirus (Figure 3a) indicated that TOA02 overcame the disadvantages of attenuated viral replication when the hTERT promoter was modified by E-boxes, Sp1-binding sites and so on. 12, 13 Additionally, preliminary pharmacokinetic and biodistribution studies conducted in xenograft models indicated long-lasting and high-level expression of GM-CSF in blood and tumor tissues (data not shown). Although the replication kinetics of adenovirus need to be addressed further, the data presented here show the potential application of TOA02 in the treatment of cancer. After preclinical pharmacology and toxicology studies were completed, a dose escalation phase I trial was initiated in patients with recurrent head and neck cancer, starting from October 2006. The data from the phase I study will be published separately when the study is finished. 
